Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duelmen – page 44

1 729 clinical trials in Duelmen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duelmen at a glance
1 729
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 729 trials in Duelmen

Open in trial search

Hyperkalaemia

Recruiting

Study on the Safety and Effectiveness of Sodium Zirconium Cyclosilicate for Children with High Potassium Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:AstraZeneca AB

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Glioblastoma

Recruiting

Study on Glioblastoma Treatment with Olaptesed Pegol and Radiation, with Bevacizumab or Pembrolizumab, for Patients with Unmethylated MGMT Promoter

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:TME Pharma AG

Study of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Endometrial cancer+4

Recruiting

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:PC14586
  • Sponsor:Pmv Pharmaceuticals Inc.

Breast cancer+1

Recruiting

Study on Detecting Hidden Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ Using [68Ga]FAPI-46 and Gadobutrol

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Universitaet Muenster

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:AstraZeneca AB

IgA nephropathy

Recruiting

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:GBG Forschungs GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duelmen

What the registry says about research in the country

01 Immune System Diseases

In Dülmen, several recruiting studies focus on immune system diseases, especially psoriasis and chronic spontaneous urticaria. The research is aimed at finding better ways to control symptoms, assess treatment benefit, and support longer-term disease management.

  • Moderate to severe plaque psoriasis
  • Mild to moderate psoriasis
  • Chronic spontaneous urticaria
  • Evaluating treatment effectiveness and safety

These trials include studies of new therapies and comparisons with established options to improve care for people living with persistent inflammatory skin conditions.

02 Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases is a major part of the local clinical trial landscape, with studies covering atopic dermatitis, acne, and different forms of psoriasis. The overall goal is to test new topical and oral treatments that may offer better symptom relief and disease control.

  • Mild to moderate atopic dermatitis
  • Papulopustular acne
  • Chronic stable plaque psoriasis
  • Comparing new treatments with approved therapies or vehicle

These studies help researchers understand how well candidate treatments reduce skin inflammation, improve visible lesions, and support longer-lasting control of chronic skin disease.

03 Parasitic Diseases

Clinical research also includes parasitic diseases, with scabies being a key focus. The studies are designed to evaluate how well standard therapies work in clearing infection and restoring skin health.

  • Scabies
  • Assessing clinical response after treatment
  • Evaluating symptom resolution and treatment success

This area reflects practical, patient-centered research aimed at confirming effective care for a common contagious skin condition.

04 Topical Treatment Development

A number of trials in the city are centered on topical medicines for inflammatory skin disorders, including gels and ointments for acne, atopic dermatitis, and psoriasis. The focus is on comparing candidate products with approved treatments and non-active controls.

  • Testing new gels and ointments
  • Comparing against reference treatments
  • Improving local symptom control

These studies aim to refine everyday treatment options that may be easier to use and more effective for patients with chronic skin conditions.

05 Long-Term Disease Control

Some research is directed at long-term disease control, looking at how well treatments maintain benefit over time in chronic conditions such as psoriasis and urticaria. This helps determine whether a therapy can keep symptoms from returning or worsening.

  • Tracking time to disease worsening
  • Monitoring treatment durability
  • Supporting chronic disease management

Such studies are especially valuable for people who need sustained relief rather than short-term improvement alone.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.